Palovarotene (R-667 RO-3300074) is a highly selective retinoic acid receptor gamma (RAR-γ) agonist that is under investigation as a potential treatment for emphysema. It is being developed by Roche. One such clinical trial found that palovarotene failed to produce any significant improvement in those with α1-antitrypsin deficiency-induced emphysema over a period of a year.
This page contains content from the copyrighted Wikipedia article "Palovarotene"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
